Loading stock data…
GNTA
$0.73+0.02 (+2.64%)
Market ClosedLast close May 1
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genenta Science S.p.A. in the Healthcare sector is trading at $0.73. The stock is currently near its 52-week low of $0.59, remaining 64.6% below its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why GNTA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.73
Potential Upside
5%
Whystock Fair Value$0.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.81%
Volume
Today's trading volume
21,626
Recent News
European Equities Traded in the US as American Depositary Receipts Higher Tuesday
European equities traded in the US as American depositary receipts were rising Tuesday morning, up 1
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business
Genenta Science SPA (NASDAQ:GNTA) is among the best Italian stocks to buy in 2026. Genenta Science SPA (NASDAQ:GNTA) will hold an extraordinary shareholders meeting on March 26. This comes on the back of the company announcing a major shift in its business strategy. Genenta Science, which has all along been concentrating on biotech programs with […]
European Equities Traded in the US as American Depositary Receipts Gain Friday
European equities traded in the US as American depositary receipts were rising on Friday morning, up
US-China Trade Optimism Lifts US Equity Futures Pre-Bell
US equity futures were up ahead of Monday's opening bell as traders monitored developments surroundi
Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism
Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology. This move highlights growing confidence in Genenta’s research trajectory. See our latest analysis for Genenta Science. Genenta Science's share price soared this week following the expanded Anemocyte collaboration, locking in a remarkable 1-day share price return of 91.95% and a 7-day return...